Medicine and Dentistry
Abdominal Cancer
52%
Acute Cholecystitis
10%
Acute Pancreatitis
10%
Adipose Tissue
8%
Adverse Event
8%
Anastomosis Leakage
19%
Antibiotics
15%
Bleeding
13%
Cancer Surgery
19%
CD3 Antigen
11%
CD8 Antigen
9%
Cell Density
11%
Cellular Infiltration
9%
Cholangitis
10%
Cholecystectomy
20%
Chronic Fatigue Syndrome
8%
Chronic Pancreatitis
28%
Circulating Tumor DNA
9%
Coeliac Disease
24%
Cohort Analysis
40%
Colectomy
22%
Colorectal Carcinoma
83%
Colostomy
9%
Comorbidity
18%
Computer Assisted Tomography
27%
Diagnosis
30%
Disease Course
10%
Disease Severity
9%
Diseases
26%
Diverticulitis
24%
DNA Mismatch Repair
9%
Dysplasia
16%
Elderly Patient
28%
Endoscopic Retrograde Cholangiopancreatography
11%
Esophageal Cancer
16%
Esophageal Cancer
9%
Esophageal Stent
11%
Esophagectomy
35%
Exocrine Pancreatic Insufficiency
8%
Fecal Microbiota Transplantation
8%
Gastrectomy
51%
Hazard Ratio
22%
Hernia
9%
Ileostomy
24%
Immune Cell Infiltration
8%
Immunity
12%
Immunocompetent Cell
13%
Immunotherapy
12%
Incisional Hernia
18%
Indoleamine 2,3 Dioxygenase
10%
Inflammatory Bowel Disease
16%
Intraductal Papillary Mucinous Tumor
24%
Laparoscopic Cholecystectomy
19%
Lung Metastasis
16%
Malignant Neoplasm
20%
Neoadjuvant Therapy
15%
Neoplasm
74%
Odds Ratio
13%
Osteoporosis
10%
Overall Survival
22%
Pancreas Cancer
27%
Pancreatic Injury
8%
Pancreatic Surgery
10%
Partial Gastrectomy
8%
Patient Referral
11%
Patient with Inflammatory Bowel Disease
10%
Placebo
11%
Postoperative Complication
50%
Prevalence
14%
Prognostic Factor
19%
Programmed Death-Ligand 1
12%
Proportional Hazards Model
8%
Prospective Study
8%
Psoas Muscle
9%
Quality of Life
34%
Randomized Clinical Trial
24%
Rectum Cancer
29%
Rectum Resection
24%
Recurrence Risk
9%
Recurrent Disease
21%
Reoperation
12%
Retrospective Cohort Study
28%
Sarcopenia
9%
Scoring System
8%
Serositis
10%
Stenting
11%
Stoma
12%
Stomach Adenocarcinoma
20%
Stroma
17%
Surgery
39%
Surgical Anastomosis
10%
Surgical Infection
12%
Symptomatic Treatment
16%
T Cell
9%
Total Stomach Resection
14%
Tumor Cell
8%
Ulcerative Colitis
24%
Upper Gastrointestinal Bleeding
8%
Urokinase Receptor
16%
Vedolizumab
9%
Keyphrases
5-year Survival
12%
90-day Mortality
11%
Absence of Evidence
9%
Acute Cholecystitis
10%
Acute Diverticulitis
24%
After Surgery
22%
Anastomotic Leak
21%
Biological Mesh
16%
Cancer Microenvironment
9%
Carbohydrate Antigen 19-9 (CA19-9)
10%
Celiac Disease
35%
Cell Density
10%
Cell-to-cell
10%
Cholecystectomy
19%
Chronic Pancreatitis
28%
Clinical Characteristics
9%
Colectomy
11%
Colorectal Cancer
75%
Comorbidity
15%
Complicated Acute Diverticulitis
9%
Computed Tomography
25%
Confidence Interval
20%
Consecutive Patients
9%
Consensus Group
10%
Disease Severity
9%
Distal Gastrectomy
9%
Elderly Patients
28%
Endoscopic Surgery
15%
Esophageal Cancer
17%
Esophageal Complications
10%
Esophageal Stent
10%
Esophagectomy
14%
Europe
16%
Exocrine Pancreatic Insufficiency
11%
Finland
100%
Gastrectomy
43%
Gastric Adenocarcinoma
20%
Gastric Cancer
44%
Gastric Cancer Surgery
9%
Gastrointestinal
11%
Gluten
9%
Hazard Ratio
18%
High Risk
13%
Immune Cell Score
9%
Incidence Rate
13%
Incidence Trends
9%
Incisional Hernia
18%
Indoleamine 2,3-dioxygenase 1 (IDO1)
10%
Inflammatory Bowel Disease
16%
Intraductal Papillary mucinous Neoplasm
16%
Intravenous Antibiotics
9%
Laparoscopic Cholecystectomy
19%
Loop Ileostomy Closure
16%
Lynch Syndrome
10%
Multicenter Cohort Study
11%
Multicenter Trial
9%
National Cohort Study
13%
Neoadjuvant Therapy
11%
Non-associated
15%
Nordic Countries
10%
Obesity
13%
Odds Ratio
11%
Oncological Outcomes
14%
Oral Antibiotics
16%
Osteoporosis
10%
Overall Survival
19%
Pancreatic Cancer
18%
Pancreatic Cyst
11%
Pancreatic Ductal Adenocarcinoma
13%
Pancreatic Surgery
10%
Placebo-controlled
9%
Population-based
42%
Population-based Study
38%
Post-esophagectomy
16%
Postoperative Complications
43%
Prognostic Factors
14%
Prognostic Role
16%
Pulmonary Metastasis
16%
Quality of Life
20%
Randomized Clinical Trial
32%
Rectal Resection
16%
Reoperation
9%
Resection
10%
Retrorectus
9%
Retrospective Cohort Study
29%
Risk Factors
11%
Robotic-assisted
9%
Sarcopenia
9%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
16%
Surgical Outcomes
13%
Surgical Site Infection
16%
Synthetic Mesh
16%
Tertiary Care Hospital
20%
Tissue Transglutaminase Antibodies
14%
Total Gastrectomy
18%
Transglutaminase 2 Inhibitor
16%
Tumor
22%
Ulcerative Colitis Patient
11%
University Hospital
13%
Vedolizumab
9%